More than five years after an initial FDA approval, Novartis is touting positive trial results for its radiotherapy Lutathera as a first-line therapy against the rare cancer that killed Apple ...

Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patients Gastroenteropancreatic ...

Basel, June 3, 2021 — Novartis today reported the final analysis from the NETTER-1 phase III study comparing treatment using Lutathera® (INN: lutetium (177Lu) oxodotreotide / USAN: lutetium Lu 177 ...

Please provide your email address to receive an email when new articles are posted on . Median PFS improved by more than 1 year for patients who received radioligand therapy. ORR improved by more than ...

Novartis AG NVS released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Radioligand ...

Perspective Therapeutics' pipeline, led by VMT-a-NET, shows promising safety and early efficacy, but lacks clear superiority over existing therapies like Lutathera so far. The company maintains a ...

The diagnosis of NETs is often delayed and approximately 10% to 20% of pediatric patients are diagnosed with metastatic disease. The approval was based on the NETTER-P trial, which evaluated Lutathera ...